318
W. Li et al.
124. Diener JL, Daniel LHA, Duerschmied D, Merhi Y, Tanguay J-F, Hutabarat R, Gilbert J,
Wagner DD, Schaub R (2009) Inhibition of von Willebrand factor-mediated platelet activation
and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J Thromb
Haemost 7(7):1155–1162
125. Spiel AO, Mayr FB, Ladani N, Wagner PG, Schaub RG, Gilbert JC, Jilma B (2009) The
aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo
platelet function in acute myocardial infarction. Platelets 20(5):334–340
126. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, Healy
JM, Boufakhreddine S, Holohan TV, Schaub RG (2007) First-in-human evaluation of anti
von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation
116(23):2678–2686
127. Arzamendi D, Dandachli F, Theoret JF, Ducrocq G, Chan M, Mourad W, Gilbert JC, Schaub
RG, Tanguay JF, Merhi Y (2011) An anti-von Willebrand factor aptamer reduces platelet
adhesion among patients receiving aspirin and clopidogrel in an ex vivo shear-induced arterial
thrombosis. Clin Appl Thromb Hemost 17(6):E70-78
128. Markus HS, McCollum C, Imray C, Goulder MA, Gilbert J, King A (2011) The von Willebrand
inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized
trial. Stroke 42(8):2149–2153
129. Ruggeri ZM (2003) Von Willebrand Factor. Curr Opin Hematol 10(2):142–149
130. Ruggeri ZM, Dent JA, Saldivar E (1999) Contribution of distinct adhesive interactions to
platelet aggregation in flowing blood. Blood 94(1):172–178
131. Oney S, Nimjee SM, Layzer J, Que-Gewirth N, Ginsburg D, Becker RC, Arepally G,
Sullenger BA (2007) Antidote-controlled platelet inhibition targeting von Willebrand factor
with aptamers. Oligonucleotides 17(3):265–274
132. Diaz JA, Wrobleski SK, Alvarado CM, Hawley AE, Doornbos NK, Lester PA, Lowe SE,
Gabriel JE, Roelofs KJ, Henke PK, Schaub RG, Wakefield TW, Myers DD Jr (2015) P-selectin
inhibition therapeutically promotes thrombus resolution and prevents vein wall fibrosis better
than enoxaparin and an inhibitor to von Willebrand factor. Arterioscler Thromb Vasc Biol
35(4):829–837
133. Romanelli A, Affinito A, Avitabile C, Catuogno S, Ceriotti P, Iaboni M, Modica J, Condorelli
G, Catalucci D (2018) An anti-PDGFRβ aptamer for selective delivery of small therapeutic
peptide to cardiac cells. PLoS ONE 13(3):e0193392
134. Han K, Liang Z, Zhou N (2010) Design Strategies for Aptamer-Based Biosensors. Sensors
(Basel) 10(5):4541–4557
135. Dollins CM, Nair S, Sullenger BA (2008) Aptamers in immunotherapy. Hum Gene Ther
19(5):443–450
136. Thiel K (2004) Oligo oligarchy-the surprisingly small world of aptamers. Nat Biotechnol
22(6):649–651
W. Li et al.
124. Diener JL, Daniel LHA, Duerschmied D, Merhi Y, Tanguay J-F, Hutabarat R, Gilbert J,
Wagner DD, Schaub R (2009) Inhibition of von Willebrand factor-mediated platelet activation
and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J Thromb
Haemost 7(7):1155–1162
125. Spiel AO, Mayr FB, Ladani N, Wagner PG, Schaub RG, Gilbert JC, Jilma B (2009) The
aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo
platelet function in acute myocardial infarction. Platelets 20(5):334–340
126. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, Healy
JM, Boufakhreddine S, Holohan TV, Schaub RG (2007) First-in-human evaluation of anti
von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation
116(23):2678–2686
127. Arzamendi D, Dandachli F, Theoret JF, Ducrocq G, Chan M, Mourad W, Gilbert JC, Schaub
RG, Tanguay JF, Merhi Y (2011) An anti-von Willebrand factor aptamer reduces platelet
adhesion among patients receiving aspirin and clopidogrel in an ex vivo shear-induced arterial
thrombosis. Clin Appl Thromb Hemost 17(6):E70-78
128. Markus HS, McCollum C, Imray C, Goulder MA, Gilbert J, King A (2011) The von Willebrand
inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized
trial. Stroke 42(8):2149–2153
129. Ruggeri ZM (2003) Von Willebrand Factor. Curr Opin Hematol 10(2):142–149
130. Ruggeri ZM, Dent JA, Saldivar E (1999) Contribution of distinct adhesive interactions to
platelet aggregation in flowing blood. Blood 94(1):172–178
131. Oney S, Nimjee SM, Layzer J, Que-Gewirth N, Ginsburg D, Becker RC, Arepally G,
Sullenger BA (2007) Antidote-controlled platelet inhibition targeting von Willebrand factor
with aptamers. Oligonucleotides 17(3):265–274
132. Diaz JA, Wrobleski SK, Alvarado CM, Hawley AE, Doornbos NK, Lester PA, Lowe SE,
Gabriel JE, Roelofs KJ, Henke PK, Schaub RG, Wakefield TW, Myers DD Jr (2015) P-selectin
inhibition therapeutically promotes thrombus resolution and prevents vein wall fibrosis better
than enoxaparin and an inhibitor to von Willebrand factor. Arterioscler Thromb Vasc Biol
35(4):829–837
133. Romanelli A, Affinito A, Avitabile C, Catuogno S, Ceriotti P, Iaboni M, Modica J, Condorelli
G, Catalucci D (2018) An anti-PDGFRβ aptamer for selective delivery of small therapeutic
peptide to cardiac cells. PLoS ONE 13(3):e0193392
134. Han K, Liang Z, Zhou N (2010) Design Strategies for Aptamer-Based Biosensors. Sensors
(Basel) 10(5):4541–4557
135. Dollins CM, Nair S, Sullenger BA (2008) Aptamers in immunotherapy. Hum Gene Ther
19(5):443–450
136. Thiel K (2004) Oligo oligarchy-the surprisingly small world of aptamers. Nat Biotechnol
22(6):649–651